Merck KGaA reports two-year follow-up results for pimicotinib in TGCT patients

Merck KGaA announced two-year follow-up results for pimicotinib in TGCT patients, showing sustained improvements in symptoms and joint function from Week 5 through two years. Tumor responses remained robust and durable, with an objective response rate of 76.2% by blinded independent review committee per RECIST v1.1.

Detected & updated continuously · Source: Nebula